Interventional Radiology Imaging

How Should You Treat Acute Pulmonary Emboli with Right Heart Failure and Head Trauma?

·
How Should You Treat Acute Pulmonary Emboli with Right Heart Failure and Head Trauma?

It’s 2 AM in the emergency department, and you are managing a complex patient. An adult with known acute bilateral central pulmonary emboli, confirmed on CT angiography, has just returned from an echocardiogram showing clear evidence of right heart failure. The reason for the echo was a syncopal event where the patient fell, sustaining head trauma with an acute intracranial hemorrhage now visible on a non-contrast head CT. The patient is teetering on the edge of decompensation. Systemic thrombolysis is off the table due to the head bleed. This article details the ACR-guided workflow for this specific, high-stakes scenario, where the primary question is how to intervene. For this presentation, the American College of Radiology rates Catheter-directed therapy pulmonary artery as Usually Appropriate.

## Who Fits This Clinical Scenario?
This guidance applies to a very specific subset of patients with pulmonary embolism (PE): adults with an established diagnosis of acute, extensive PE involving the central pulmonary arteries who show objective signs of right heart strain or failure (e.g., on an echocardiogram or CT). The critical distinguishing feature is a concurrent absolute contraindication to systemic thrombolysis, in this case, an acute intracranial hemorrhage from recent trauma. This patient is often categorized as having a “submassive” or intermediate-high-risk PE, but with a complication that severely limits standard advanced therapies.

This workflow is NOT for:

  • Patients with massive PE and sustained hypotension: These patients are in cardiogenic shock and may require more aggressive resuscitation, including systemic thrombolysis (if no contraindications) or extracorporeal membrane oxygenation (ECMO). This is a distinct ACR scenario.
  • Patients with submassive PE who are candidates for systemic thrombolysis: If there were no intracranial hemorrhage, the risk-benefit calculation for systemic lytics would be entirely different.
  • Patients with low-risk PE: Individuals with smaller, more peripheral emboli, no right heart strain, and normal vital signs are typically managed with anticoagulation alone and do not require advanced intervention.

Correctly identifying this patient—one with significant clot burden and heart strain who cannot receive lytics—is the crucial first step.

## What Diagnoses Are You Working Up in This Scenario?
At this stage, the diagnosis of acute pulmonary embolism is already confirmed. The clinical “workup” is no longer about identifying the cause of symptoms but about risk-stratifying the patient and selecting the appropriate therapy. The key considerations are confirming the severity of the PE and the absolute contraindication to systemic lytics.

Intermediate-High-Risk (Submassive) Pulmonary Embolism: This is the primary working diagnosis for management. The patient is normotensive but has evidence of right ventricular (RV) dysfunction (seen on echo) and likely myocardial injury (elevated troponin). This combination signifies a high risk of clinical deterioration and mortality without effective intervention to reduce the clot burden and offload the strained right ventricle.

Absolute Contraindication to Systemic Thrombolysis: The presence of acute intracranial hemorrhage is a non-negotiable contraindication. This finding fundamentally alters the therapeutic algorithm, forcing a shift away from systemic lytic agents toward therapies that offer a more localized effect with a lower risk of exacerbating the head bleed.

Impending Hemodynamic Collapse: While the patient may currently be normotensive, the combination of syncope and RV failure is a harbinger of potential decompensation. The clinical team must act under the assumption that the patient’s stability is tenuous. The goal of therapy is to prevent progression to obstructive shock, which carries a very high mortality rate.

## Why Is Catheter-directed Therapy of the Pulmonary Artery the Recommended Intervention?
For a patient with a large clot burden, RV strain, and an absolute contraindication to systemic lytics, catheter-directed therapy is rated Usually Appropriate because it directly addresses the pathophysiology while navigating the significant bleeding risk. This interventional radiology procedure involves advancing a catheter through the venous system into the pulmonary arteries to treat the clot locally.

The rationale includes:

  • Targeted Clot Treatment: Unlike systemic thrombolysis, which circulates lytic drugs throughout the body, catheter-directed techniques deliver treatment directly to the site of the thrombus. This can be done via low-dose infusion of thrombolytics (catheter-directed thrombolysis) or mechanical removal/fragmentation of the clot (catheter-directed embolectomy). This localization dramatically reduces the systemic dose of lytic agent, or avoids it altogether, lowering the risk of worsening the intracranial hemorrhage.
  • Rapid RV Decompression: By physically removing or dissolving the central clot, the procedure can quickly reduce pulmonary artery pressure and alleviate the afterload on the right ventricle. This can reverse the cycle of RV failure before it becomes irreversible. The diagnosis of extensive bilateral central emboli, which sets this cascade in motion, is typically made with high-quality imaging. Once you’ve decided on intervention, our protocol guide covers the technique, contrast, and reading principles for the initial diagnostic study: CTA Pulmonary (PE Protocol).

### Why Alternatives Are Rated Lower

  • Systemic Thrombolysis: This is rated Usually not appropriate. Administering a full dose of a lytic agent to a patient with an active intracranial bleed poses an unacceptably high risk of catastrophic hemorrhage expansion and death.
  • Anticoagulation Alone: Rated as May be appropriate, this is the baseline therapy for all PEs but is often insufficient for this high-risk presentation. Anticoagulation prevents new clot formation but relies on the body’s slow endogenous fibrinolysis to break down the existing large clot. In the face of RV failure, this may be too slow to prevent hemodynamic collapse.
  • Surgical Embolectomy: Rated as May be appropriate (Disagreement), this is an open-heart procedure to physically remove the emboli. It is highly effective but also highly invasive, requiring cardiopulmonary bypass and carrying significant surgical risk. It is typically reserved for patients who are not candidates for catheter-based therapies, in whom the procedure has failed, or at centers with specific surgical expertise.

## What’s Next After Catheter-directed Therapy? Downstream Workflow
The post-procedure workflow is focused on managing the competing risks of thrombosis and bleeding, while monitoring for clinical improvement.

  • If the procedure is successful: The patient should be monitored in an intensive care unit (ICU). The immediate goals are to assess for improvement in hemodynamics and RV function, often with a follow-up echocardiogram within 24-48 hours. The most complex decision is anticoagulation. This requires a careful, multidisciplinary discussion involving interventional radiology, pulmonology/critical care, hematology, and neurosurgery/neurology to determine the safest timing and agent to restart anticoagulation, balancing the risk of PE recurrence against the risk of expanding the intracranial hemorrhage.
  • If the procedure is technically unsuccessful or the patient remains unstable: The situation is critical. The team must immediately reconvene to consider escalating therapy. This may involve a rescue surgical embolectomy or placing the patient on ECMO as a bridge to recovery or further intervention.
  • If the patient’s bleeding worsens: If there is evidence of worsening intracranial hemorrhage, anticoagulation must be held and potentially reversed. Management becomes focused on neurocritical care support, and further attempts to treat the PE may be deferred until the bleeding is controlled.

## Pitfalls to Avoid (and When to Get Help)
In this complex scenario, several pitfalls can lead to poor outcomes.

  • Delaying the Decision: Time is critical. Prolonged RV strain can lead to irreversible injury. Hesitation in activating an advanced PE response can allow the patient to deteriorate into cardiogenic shock.
  • Misjudging Bleeding Risk: Do not underestimate the risk of systemic lytics. The presence of an acute intracranial hemorrhage is a hard stop, and “reduced-dose” systemic strategies are not validated and remain high-risk.
  • Lack of Multidisciplinary Input: This case should not be managed by a single service. A Pulmonary Embolism Response Team (PERT) model, involving specialists from critical care, interventional radiology, cardiac surgery, and hematology, is ideal for rapid, consensus-based decision-making.
  • Neglecting the Head Injury: The PE is the immediate life threat, but the intracranial hemorrhage requires concurrent management. Close collaboration with neurosurgery or neurology is essential to monitor the bleed and guide anticoagulation decisions.

If the patient develops sustained hypotension or worsening hypoxemia despite initial measures, escalate immediately to your institution’s PERT or critical care response team to discuss emergent surgical or mechanical circulatory support options.

## Related ACR Topics and Tools
This article covers one specific, high-acuity scenario. For a comprehensive overview of all clinical variants in this topic, see our parent guide. For other scenarios or to explore the underlying data, the tools below provide direct access to appropriateness criteria, imaging protocols, and dose information.

Frequently Asked Questions

Why is anticoagulation alone not enough for this patient?

While anticoagulation is essential to prevent further clot formation, it does not actively break down the large, existing emboli that are causing right heart failure. In a patient who has already experienced syncope and has objective RV strain, waiting for the body’s natural clot-dissolving process is often too slow and risks sudden hemodynamic collapse. The goal of advanced therapy is to rapidly reduce the clot burden.

What specifically makes catheter-directed therapy safer than systemic thrombolysis in this case?

The primary safety advantage is the localization of treatment. Systemic thrombolysis exposes the entire body to powerful clot-busting drugs, creating a high risk of bleeding at any vulnerable site, including the acute intracranial hemorrhage. Catheter-directed therapy delivers a much lower dose of medication (or uses a mechanical device with no medication) directly into the pulmonary artery clot, minimizing systemic exposure and significantly reducing the risk of worsening the head bleed.

When would surgical embolectomy be chosen over catheter-directed therapy?

Surgical embolectomy, an open-heart procedure, is generally considered more invasive. It might be chosen if catheter-based therapies are not available at an institution, if they have failed, or if the patient has other intracardiac issues (like a large thrombus-in-transit through a PFO) that are better addressed surgically. The decision is highly dependent on local expertise and patient-specific factors, which is why the ACR rates it ‘May be appropriate (Disagreement)’.

What is the role of a Pulmonary Embolism Response Team (PERT) in this scenario?

A PERT is a multidisciplinary team designed for rapid response to high-risk PE cases like this one. Its role is to bring together experts from critical care, interventional radiology, cardiac surgery, and hematology for a real-time consultation. This facilitates a rapid, consensus-based decision on the optimal therapy, avoiding delays and ensuring all treatment options and risks are considered simultaneously.

How is anticoagulation managed after the procedure, given the head bleed?

This is one of the most challenging aspects of post-procedure care. There is no single right answer, and it requires a careful, individualized risk-benefit analysis. The decision to restart anticoagulation—and with which agent (e.g., heparin drip vs. a DOAC)—is made in close consultation with neurology or neurosurgery. They will typically want to see stability or resolution of the hemorrhage on follow-up head imaging before anticoagulation is cautiously resumed, often starting at a lower intensity.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 30, 2026